THE Therapeutic Goods Administration is currently reviewing the use of MI (methylisothiazolinone) in skincare because it can cause allergic contact dermatitis.
Ego Pharmaceuticals has welcomed the move, citing research published in the Medical Journal of Australia which found the rate of allergic reactions to MI jumped from 3.5% to 11.3% over a two-year period from 2011 to 2013.
The above article was sent to subscribers in Pharmacy Daily's issue from 24 Jul 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 24 Jul 17
